Avenue Therapeutics Inc. buy Ruckelsbuckel
Start price
08.10.22
/
60%
€2.86
Target price
08.10.23
€5.00
Performance (%)
9.28%
End price
16.10.22
€3.12
Summary
This prediction ended on 16.10.22 with a price of €3.12. The BUY prediction by Ruckelsbuckel finished with a performance of 9.28%. Ruckelsbuckel has 60% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Avenue Therapeutics Inc. | - | - | - |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% |
According to Ruckelsbuckel what are the pros and cons of Avenue Therapeutics Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Standard Investments for future growth
ROE higher than 10% per year
Very capable Management
Very good company culture
Leading role in innovation
Some uniques
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is very important
Stable Large shareholder and/or long term investor
Top 10 in its market
Known brand
Very Future proof/growth oriented business model
Cons
High valuation
Very low/no dividend yield expected
negative Cash Flow expected
Bad rating
High risks in the balance sheet
Increased challenges to pay loans and raise capital
High risks for its business
Significant cyclical dependencies